The presence of bone metastases is indicative of disseminated disease and typically indicates a short-term prognosis in cancer patients. Palliation of symptoms is the primary goal of therapy, with multidisciplinary efforts yielding the best results. New classes of drugs, such as bisphosphonates that significantly increase the time to first skeletal-related event (SRE), represent useful tools for the treatment of bone metastases. While the optimal duration of therapy needs to be defined, there is clinical benefit derived from the use of this class of agents. A potential role for bisphosphonates in the prevention of bone metastases is under current evaluation in clinical trials encompassing different solid tumor types. In combination with ongoing clinical trials, basic research to identify potential novel targets in the tumor cells-bone microenvironment will further define future strategies in the treatment of bone metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2005.03.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: We hypothesised that applying radiomics to [F]PSMA-1007 PET/CT images could help distinguish Unspecific Bone Uptakes (UBUs) from bone metastases in prostate cancer (PCa) patients. We compared the performance of radiomic features to human visual interpretation.
Materials And Methods: We retrospectively analysed 102 hormone-sensitive PCa patients who underwent [F]PSMA-1007 PET/CT and exhibited at least one focal bone uptake with known clinical follow-up (reference standard).
Periacetabular metastases: Proposed extension of the Harrington classification.
J Orthop
August 2025
Department of Orthopaedic Surgery, Hospital Clínico San Carlos, Spanish National Reference Center for Musculoskeletal Oncological Surgery, Calle Del Prof Martín Lagos, S/N, Moncloa, 28040, Madrid, Spain.
Objectives: To describe the functional outcomes, complications, and reconstruction types in patients with periacetabular metastases and to propose an extension of the Harrington classification.
Methods: Twenty-eight patients (13 males, 15 females) with a mean age of 63.8 ± 15.
Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.
Int Urol Nephrol
January 2025
Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Baden-Württemberg, Germany.
Purpose: To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Methods: Retrospective analysis was conducted on mCRPC patients treated with docetaxel at a German tertiary center between March 2010 and November 2023. Prognostic clinical and laboratory factors were analyzed using uni- and multivariable logistic regression.
A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration.
BJC Rep
January 2025
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background: Osteosarcoma is the most common malignant bone tumour with limited treatment options and poor outcomes in advanced metastatic cases. Current immunotherapies show limited efficacy, highlighting the need for novel therapeutic approaches. Systemic immune activation by Toll-like receptor 4 (TLR4) immunostimulants has shown great promise; however, current TLR4 agonists' toxicity hinders this systemic approach in patients with osteosarcoma.
View Article and Find Full Text PDFInteractive segmentation for accurately isolating metastatic lesions from low-resolution, large-size bone scintigrams.
Phys Med Biol
January 2025
Charles Sturt University, Albury-Wodonga, NSW, Albury, New South Wales, 2640, AUSTRALIA.
Bone is a common site for the metastasis of malignant tumors, and Single Photon Emission Computed Tomography (SPECT) is widely used to detect these metastases. Accurate delineation of metastatic bone lesions in SPECT images is essential for developing treatment plans. However, current clinical practices rely on manual delineation by physicians, which is prone to variability and subjective interpretation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!